Here are 18 key notes on orthopedic and spine device companies from the past week.
DJO Global reported a potential breach of patient information that affects patients who underwent surgery with their products at Las Vegas-based St. Rose Dominican Hospital between July 17 and Oct. 16, 2017.
Stryker reported a 10 percent boost of net sales to $3.5 billion in the fourth quarter of 2017.
NuVasive expects 2017 revenue to hit $1.03 billion, in line with previously reported guidance with the lingering impact of Hurricane Maria factored in.
Mazor expects 2017 revenue will hit $65 million and reports the company sold 27 robotic guidance systems in the fourth quarter.
K2M will likely see revenue between $67.3 million and $67.9 million in fiscal year 2017, reflecting a 9 percent to 10 percent year-over-year increase.
Globus Medical expects 2017 fourth quarter sales to reach $175.5 million, a 15.8 percent increase compared to the 2016 fourth quarter.
For the fourth quarter of 2017, SeaSpine will likely see revenue between $34.2 million and $34.4 million, a 6 percent increase from the fourth quarter of 2016.
Medtronic presented a plan to restructure the company at the J.P. Morgan Healthcare Conference and reported some of the details in a Securities and Exchange Commission filing.
Researchers enrolled the first patient in Medtronic's Vectors Post Market Clinical Study at Wilmington, Del.-based The Center for Interventional Pain & Spine.
Johnson & Johnson CEO Alex Gorsky spoke with CNBC at the J.P. Morgan Health Care Conference, discussing tax reforms and the outlook for mergers and acquisitions in the medtech space.
Alphatec reported that fourth quarter 2017 revenue is expected to be between $25.9 million and $26.3 million.
Orthofix expects to see roughly $117 million in fourth quarter 2017 sales.
4WEB Medical saw a 57 percent boost in year-over-year growth in 2017.
Providence Medical Technology named Jeremy Laynor vice president of U.S. sales and highlighted the publication of two studies regarding its cervical fusion technology.
The FDA approved Boston Scientific's Spectra WaveWriter Spinal Cord Stimulator System.
On Jan. 10, Misonix's president and CEO rang the Nasdaq Stock Market Closing Bell.
Spinal Elements appointed Paul Graveline its new executive vice president and chief commercial officer.
Medical device manufacturer Stimwave agreed to over $50 million in financing from undisclosed investors for its consumer launch of an opioid-free pain management microchip stimulator.